CORD-19:68a7101a90454172c91785d8c352f776a82df5d4 / 335156-335528 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T3286","span":{"begin":0,"end":372},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}

{"project":"Epistemic_Statements","denotations":[{"id":"T719","span":{"begin":161,"end":372},"obj":"Epistemic_statement"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T234","span":{"begin":0,"end":372},"obj":"Sentence"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T765","span":{"begin":13,"end":16},"obj":"Phenotype"},{"id":"T766","span":{"begin":65,"end":78},"obj":"Phenotype"},{"id":"T767","span":{"begin":80,"end":91},"obj":"Phenotype"}],"attributes":[{"id":"A765","pred":"hp_id","subj":"T765","obj":"http://purl.obolibrary.org/obo/HP_0002383"},{"id":"A766","pred":"hp_id","subj":"T766","obj":"http://purl.obolibrary.org/obo/HP_0011096"},{"id":"A767","pred":"hp_id","subj":"T767","obj":"http://purl.obolibrary.org/obo/HP_0003447"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1380","span":{"begin":211,"end":213},"obj":"Body_part"}],"attributes":[{"id":"A1380","pred":"uberon_id","subj":"T1380","obj":"http://purl.obolibrary.org/obo/UBERON_0001877"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T2207","span":{"begin":13,"end":16},"obj":"Disease"},{"id":"T2210","span":{"begin":46,"end":63},"obj":"Disease"},{"id":"T2211","span":{"begin":211,"end":213},"obj":"Disease"},{"id":"T2188","span":{"begin":13,"end":16},"obj":"Disease"},{"id":"T83190","span":{"begin":46,"end":63},"obj":"Disease"},{"id":"T43938","span":{"begin":211,"end":213},"obj":"Disease"}],"attributes":[{"id":"A2207","pred":"mondo_id","subj":"T2207","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A2208","pred":"mondo_id","subj":"T2207","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A2209","pred":"mondo_id","subj":"T2207","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A2210","pred":"mondo_id","subj":"T2210","obj":"http://purl.obolibrary.org/obo/MONDO_0004466"},{"id":"A2211","pred":"mondo_id","subj":"T2211","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"},{"id":"A33739","pred":"mondo_id","subj":"T2188","obj":"http://purl.obolibrary.org/obo/MONDO_0005134"},{"id":"A13157","pred":"mondo_id","subj":"T2188","obj":"http://purl.obolibrary.org/obo/MONDO_0019956"},{"id":"A6693","pred":"mondo_id","subj":"T2188","obj":"http://purl.obolibrary.org/obo/MONDO_0005156"},{"id":"A37042","pred":"mondo_id","subj":"T83190","obj":"http://purl.obolibrary.org/obo/MONDO_0004466"},{"id":"A94781","pred":"mondo_id","subj":"T43938","obj":"http://purl.obolibrary.org/obo/MONDO_0005301"}],"text":"Treatment of EAE animals with ALLO diminished neuroinflammation, demyelination, axonal loss together and suppression of neurobehavioral abnormalities (pb 0.05). microRNA dysregulation potentially contributes to MS pathogenesis by altering neurosteroid expression leading to selective suppression of ALLO expression and ensuing adverse effects on oligodendrocyte viability."}